ArticleJournal of the National Cancer Institute2023
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials.
Article in Journal of the National Cancer Institute, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of health-related quality of life outcomes in psychosocial intervention trials for adolescent and young adult cancer survivors.Critical reviews in oncology/hematology · 2023Pooled it
- Group-based trajectories of health-related quality of life among pediatric patients with high-risk Hodgkin lymphoma.Journal of the National Cancer Institute · 2025Trial
- Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Factors correlated with financial hardship among cancer patients during the COVID-19 pandemic.PloS one · 2026Article
- Defining and measuring tolerability in pediatric, adolescent, and young adult oncology: The essential voices.Cancer · 2025Review
- Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination.Journal of the National Cancer Institute · 2025Article
- Health-Related Quality of Life in Patients with Colorectal Cancer: A Comparison Between Those With and Without Colostomy.Journal of caring sciences · 2025Review
- The Impact of a Personal Cancer Diagnosis on the Psychological Health of Adolescent/Young Adult Cancer Survivors: A Mixed Methods Study.Psycho-oncology · 2025Article
- Advancing Global Cancer Symptom Science: Insights and Strategies From the Inaugural Cancer Symptom Science Expert Meeting.Oncology nursing forum · 2025Article
- Advancing Global Cancer Symptom Science: Insights and Strategies from the Inaugural Cancer Symptom Science Expert Meeting.Seminars in oncology nursing · 2025Article
- Cancer care for adolescents and young adults under the age of 50 in Saudi Arabia: policy review, research gaps, and future directions.EClinicalMedicine · 2025Review
- From Surviving to Thriving: Key Considerations for Weight Control Across Diverse Cancer Survivorship Populations.Obesity science & practice · 2024Review
- Article
- Exploring Adolescent and Young Adult Cancer Survivors' Experience with Cancer Treatment-Related Symptoms: A Qualitative Analysis of Semi-Structured Interviews.Journal of adolescent and young adult oncology · 2024Article
- Patient-Reported Quality of Life at Diagnosis in Adolescent and Young Adults With Cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2024Article
- Rational combination platform trial design for children and young adults with diffuse midline glioma: A report from PNOC.Neuro-oncology · 2024Article
- Psychological Outcomes in Adolescent and Young Adult Cancer Survivors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
- Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma.Journal of personalized medicine · 2024Article
- Review
- Children's Oncology Group 2023 blueprint for research: Adolescent and young adult oncology.Pediatric blood & cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Disparities in care, treatment-related toxicity and health-related quality of life (HRQoL) for adolescents and young adults (AYAs, aged 15-39 years) with cancer are under-addressed partly because of limited collection of patient-reported outcomes (PROs) in cancer clinical trials (CCTs). The AYA years include key developmental milestones distinct from younger and older patients, and cancer interrupts attainment of critical life goals. Lack of consensus on a standardized approach to assess HRQoL and treatment-related toxicity in AYA CCTs has limited the ability to improve patient outcomes. The National Cancer Institute's Clinical Trials Network AYA PRO Task Force was assembled to reach consensus on a core set of PROs and foster its integration into AYA CCTs. Eight key considerations for selecting the core PRO AYA battery components were identified: relevance to AYAs; importance of constructs across the age continuum; prioritization of validated measures; availability of measures without licensing fees; availability in multiple languages; applicability to different cancer types and treatments; ability to measure different HRQoL domains and toxicities; and minimized burden on patients and sites. The Task Force used a modified Delphi approach to identify key components of the PRO battery. The Patient-Reported Outcomes Measurement Information System (PROMIS) and the PRO Common Terminology Criteria for Adverse Events Measurement System met all criteria and were selected to assess HRQoL and treatment toxicity, respectively. Investigators are rapidly incorporating the recommendations of the Task Force into AYA trials. Inclusion of a standardized assessment of HRQoL and treatment toxicities in AYA CCTs is a vital first step to develop interventions to improve health outcomes for AYAs diagnosed with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.